论文部分内容阅读
目的:研究酮替芬对变应性鼻炎-哮喘综合征患者呼出气一氧化氮(FeNO)的影响。方法:选取2016-01-2017-03期间治疗的84例支气管哮喘伴有变应性鼻炎患者,采用随机数字表分为观察组(42例)和对照组(42例)。对照组采用止咳、化痰、吸入激素平喘治疗,观察组在对照组基础上联用酮替芬(1mg/次,2次/d)口服处理,治疗1个月后对比分析2组患者FeNO、IL-17的变化情况。结果:治疗前,2组患者一般情况、FeNO测定结果差异无统计学意义(P>0.05)。治疗后,观察组治疗有效率增高更明显(P<0.05);2组FeNO、IL-17均降低(P<0.05,P<0.01),且观察组较对照组下降更明显,均差异有统计学意义(P<0.01)。结论:酮替芬可明显降低变应性鼻炎-哮喘综合征患者的FeNO,降低气道炎症反应,其部分机制可能与降低炎症因子IL-17有关。
Objective: To investigate the effect of ketotifen on exhaled nitric oxide (FeNO) in patients with allergic rhinitis - asthma syndrome. Methods: Eighty-four patients with bronchial asthma and allergic rhinitis treated during the period of 2016-01-2017-03 were divided into observation group (n = 42) and control group (n = 42) using random number table. The control group was treated with antitussive, phlegm and inhaled hormone asthma. The observation group was treated with ketotifen (1mg / time, twice daily) orally on the basis of the control group. After a month of treatment, the FeNO , IL-17 changes. Results: Before treatment, there was no significant difference in FeNO measurement between the two groups (P> 0.05). After treatment, the effective rate of observation group increased more obviously (P <0.05); FeNO and IL-17 of two groups decreased (P <0.05, P <0.01), and the observation group decreased more obviously than the control group Significance (P <0.01). Conclusion: Ketotifen can significantly reduce FeNO and reduce airway inflammatory response in patients with allergic rhinitis-asthma syndrome, and some mechanisms may be related to the reduction of inflammatory factor IL-17.